How good is "Good Enough"? the case for varying standards of evidence according to need for new interventions in HIV prevention

American Journal of Bioethics

Volumn 12, Issue 6, 2012, Pages 21-30

  Haire, Bridget ^a   Kaldor, John ^b   Jordens, Christopher F C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

AIDS; Biomedical research; Human subjects research; Regulatory issues; Research ethics

Indexed keywords

ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ORGANOPHOSPHORUS COMPOUND; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ARTICLE; DRUG COMBINATION; EQUIPOISE; ETHICAL THEORY; ETHICS; EVIDENCE BASED MEDICINE; FEMALE; FOOD AND DRUG ADMINISTRATION; GEL; HEALTH CARE DELIVERY; HEALTH SERVICE; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVAGINAL DRUG ADMINISTRATION; MALE; METHODOLOGY; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROSTITUTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH ETHICS; RESEARCH SUBJECT; STANDARD; UNITED STATES;

ADENINE; ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, ORAL; ANTI-HIV AGENTS; DEOXYCYTIDINE; DRUG COMBINATIONS; ETHICAL ANALYSIS; ETHICAL THEORY; ETHICS, RESEARCH; EVIDENCE-BASED MEDICINE; FEMALE; GELS; GUIDELINES AS TOPIC; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES NEEDS AND DEMAND; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; PRIMARY PREVENTION; PROSTITUTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH SUBJECTS; THERAPEUTIC EQUIPOISE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84863769208     PISSN: 15265161     EISSN: 15360075     Source Type: Journal    
DOI: 10.1080/15265161.2012.671887     Document Type: Article

References (47)

1. Abdool Karim, Q., S. S. Abdool Karim, J. A. Frohlich, et al. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
2. Anderson, R. M., and G. P. Garnett. 1996. Low-efficacy HIV vaccines: potential for community-based intervention programmes. Lancet 348 (9033): 1010-1013.
3. Angell, M. 1997. The ethics of clinical research in the third world. New England Journal of Medicine 337(12): 847-849.
4. Ashcroft, R. 1999. Equipoise, knowledge and ethics in clinical research and practice. Bioethics 13(3-4): 314-326.
5. AVAC. 2010. "Frequently Asked Questions about PrEP and the iPrEx Trial," 6-7. AVAC, November 23. Available at: http://www.avac.org/ht/a/GetDocumentAction/i/31348 (accessed January 28, 2011).
6. Bloom, B. R. 1998. The highest attainable standard: Ethical issues in AIDS vaccines. Science 279: 186-188.
7. Centers for Disease Control. 2010. Pre-exposure prophylaxis (PrEP) for HIV prevention: Promoting safe and effective use in the United States. Press statement. November 23. Available at http://www.cdc.gov/nchhstp/newsroom/PrEPforHIVFactSheet.html (accessed January 23, 2010).
8. Centers for Disease Control. 2011. Interim guidance: Preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. Morbidity and Mortality Weekly Report 60(3): 65-68.
9. Connor, E. M., R. S. Sperling, R. Gelber, et al. 1994. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with Zidovudine treatment. New England Journal of Medicine 331(18): 1173-1180.
10. CONRAD. 2010. FDA and CONRAD chart U.S. regulatory path for 1% tenofovir gel for HIV prevention: FDA has granted Fast Track approval designation for 1% tenofovir gel. Press statement. October 25. Available at: http://www.natap.org/2010/newsUpdates/11011001.htm (accessed January 23, 2010).
11. Edgar, H., and D. Rothman. 1990. New rules for new drugs: The challenge of AIDS to the regulatory process. Milbank Quarterly 68(suppl. 1): 111-142.
12. Fried, C. 1974. Medical experimentation: Personal integrity and social policy. Amsterdam: North-Holland Publishing.
13. Freedman, B. 1987. Equipoise and the ethics of clinical research. New England Journal of Medicine 317(3): 141-145.
14. Global Campaign for Microbicides. 2010. Statement on FDA regulatory pathway for 1% tenofovir. Available at: http://www.globalcampaign.org/clientfiles/CONRAD%20FDA%20TFV%20GCM%20Statement.doc (accessed December 1, 2010).
15. Grant, R. M., J. R. Lama, P. Anderson, et al. 2010. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New England Journal of Medicine 363(27): 2587-2599.
16. Halpern, S. 2006. Evidence-based equipoise and research responsiveness. The American Journal of Bioethics 6(4): 1-4.
17. Hamburg, M. 2010. Innovation, regulation, and the FDA. New England Journal of Medicine 363(23): 2228-2232.
18. Heise, L. L., C. Watts, A. Foss, et al. 2011. Apples and oranges? Interpreting success in HIV prevention trials. Contraception 83(1): 10-15.
19. Jansen, L. A. 2005. A closer look at the bad deal trial: Beyond clinical equipoise. Hastings Center Report 35(5): 29-36.
20. Kopelman, L. 1986. Consent and randomised clinical trials: Are there moral or design problems? Journal of Medicine and Philosophy 11: 317-345.
21. London, A., & Zollman, K. 2010. Research at the auction block: Problems for the fair benefits approach to international research. Hastings Center Report 40(4): 34-45.
22. Lurie, P. and S. M. Wolfe. 1997. Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. New England Journal of Medicine 337(12): 853-856.
23. Macklin, R. 1999. Against relativism: Cultural diversity and the search for ethical universals in medicine. New York: Oxford University Press.
24. Macklin, R. 2001. After Helsinki: Unresolved issues in international research. Kennedy Institute of Ethics Journal 11(1): 17-36.
25. Macklin, R. 2004. Double standards in medical research in developing countries. New York: Cambridge University Press.
26. Macklin, R. 2010. Intertwining biomedical research and public health in HIV microbicide research. Public Health Ethics 3(3): 199-209.
27. McGrory, E., P S Hankins, C Paxton and L. Heise. 2010. Standards of prevention in HIV prevention trials: Consultation report and recommendations. Washington, DC: Global Campaign for Microbicides at PATH.
28. Merkatz, R. B., and S. W. Junod. 1994. The historical background of changes in FDA policy on the study and evaluation of drugs in women. Academic Medicine 69(9): 703-707.
29. Miller, F. G., and H. Brody. 2003. A critique of clinical equipoise: Therapeutic misconception in the ethics of clinical trials. Hastings Center Report 33(3): 19-28.
30. Miller, P. B., and C. Weijer. 2007. Equipoise and the duty of care in clinical research: A philosophical response to our critics. Journal of Medicine and Philosophy 32(2): 117-133.
31. Padian, N. S., A. Buvé, J. Balkus, D. Serwadda, and W. Cates, Jr. 2008. Biomedical interventions to prevent HIV infection: Evidence, challenges, and way forward. Lancet 372(9638): 585599.
32. Peterson L., D. Taylor, R Roddy, et al. 2007. Tenofovir disoproxil fumarate for prevention of HIV infection in women: A Phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clinical Trials 2: e27.
33. Rennie, S., J. Sugarman, and the HPTN Ethics Working Group. 2009. HIV PreventionTrials Network ethics guidance for research. HIV PreventionTrials Network. Available at: http://www.hptn.org/web%20documents/EWG/HPTNEthicsGuidance020310.pdf (accessed December 1, 2010).
34. Schüklenk, U. 2010. Calling it a day on proceduralism in bioethics? Bioethics 24(9): 1.
35. Slack, C., M. Stobie, C. Milford, et al. 2005. Provision of HIV treatment in HIV preventive vaccine trials: a developing country perspective. Social Science & Medicine 60(6): 1197-1208.
36. Stadler, J., and E. Saethre. 2010. Blockage and flow: Intimate experiences of condoms and microbicides in a South African clinical trial. Culture, Health & Sexuality: An International Journal for Research, Intervention and Care 13(1): 31-34.
37. Stone, A. 2010. Regulatory issues in microbicide development. Geneva, Switzerland: World Health Organisation. Available at: http://whqlibdoc.who.int/publications/2010/9789241599436eng.pdf.
38. UNAIDS. 2010a. 2010: A global view of HIV infection. Joint United Nations Programme on HIV/AIDS (UNAIDS). Available at: http://www.unaids.org/documents/201011232010HIVPrevalenceMapem.pdf (accessed January 23, 2011).
39. UNAIDS. 2010b. Global report: UNAIDS report on the global AIDS epidemic 2010. Joint United Nations Programme on HIV/AIDS (UNAIDS). Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2010/20101123globalreporten%5B1%5D.pdf (accessed January 23, 2011).
40. UNAIDS. 2011. Good participatory practice guidelines for biomedical HIV prevention trials. 2nd ed. (June 2011) Joint United Nations Programme on HIV/AIDS.
41. UNAIDS/WHO. 2007. Ethical considerations in biomedical HIV prevention trials [monograph]. Joint United Nations Programme on HIV/AIDS (UNAIDS). Available at: http://data.unaids.org/pub/Report/2007/jc1399ethicalconsiderationsen.pdf
42. Van Damme, L., G. Ramjee, M. Alary, et al. 2002. Effectiveness of COL-1492, nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial. Lancet 360: 971-977.
43. Van Damme, L., R. Govinden, F. Mirembe, et al. 2008. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine 359: 463-472.
44. van Griensven, F., J. W. de Lind van Wijngaarden, S. Baral, et al. 2009. The global epidemic of HIV infection among men who have sex with men. Current Opinion in HIV and AIDS 4(4): 300-307.
45. Varmus, H., and D. Satcher. 1997. Ethical complexities of conducting research in developing countries. New England Journal of Medicine 337(14): 1003-1005.
46. Vermund, S. H. 1998. Rationale for the testing and use of a partially effective HIV vaccine. AIDS Research and Human Retroviruses Suppl. 3: S321-S323.
47. World Medical Association. 2008. Declaration of Helsinki, amended. Originally published 1964. Available at: http://www.wma.net/en/30publications/10policies/b3/index.html